Kraenzlin et al. Supplemental Figure 1

Sep 21, 2014

10 likes | 87 Views

µV. 2.0e+5. PYD. 1.5e+5. ISTD. Fluorescence (295/400 nm). 1.0e+5. DPD. 0.5e+4. 0.0. -0.5e+4. 2. 4. 6. 8. 10. 12. Time (min). Kraenzlin et al. Supplemental Figure 1. Supplemental Figure 1:

Share Presentation

Embed Code

Link

pyd
deoxypypridinoline dpd
pyridinoline pyd
internal standard
supplemental figure 1
fluorescence 295 400 nm

luann

Download Presentation

Kraenzlin et al. Supplemental Figure 1

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

µV 2.0e+5 PYD 1.5e+5 ISTD Fluorescence (295/400 nm) 1.0e+5 DPD 0.5e+4 0.0 -0.5e+4 2 4 6 8 10 12 Time (min) Kraenzlin et al. Supplemental Figure 1 Supplemental Figure 1: Separation of urinary pyridinium crosslinks, pyridinoline (PYD) and deoxypypridinoline (DPD), by reverse phase high performance liquid chromatography;(ISTD, internal standard)

Lim et al, Supplemental Figure S1.

Lim et al, Supplemental Figure S1. . a/b. a. a. b/c. a/b. c/d. c/d. c/d. d. e. Arsenic. Plant height (Cm). f. g. [mg/Kg]. 1.5. 5.0. 7.0. 0. 10. 50. 100. 150. 0. 200. 300. 400. 500. 0. As[ μ M]. Cadmium. a/b. a. b. b. c. c. d. d. d/e. e. f. g.

157 views • 5 slides

Patel et al Supplemental Figure S4

A . Patel et al Supplemental Figure S4. 4.1 ± 1.9. SK-ES-1. 13.0 ± 3.8. SK- N-MC. 0. 4. 12. RASSF1A Fold Induction with 5-AZA treatment. B . 39.5 ± 14.5. SK-ES-1. 185.5 ± 45.6. SK- N-MC. 24.3 ± 5.9. A673. 0. 100. 150. 200. 50. CALCA Fold Induction with 5-AZA treatment.

97 views • 1 slides

Supplemental Figure 3. Kiem et al.

1500. 600. 300. 200. 100. 1500. 600. 300. 200. 100. Supplemental Figure 3. Kiem et al. a. Copy Number in Foamy Transduced Lymphocytes. 3. 2. Copy Number. 1. 0. FV-SMPGW. FV-UsI-SMPGW. FV-HsI-SMPGW. FV-SC46-IMPGW. FV-UsI-SC46-IMPGW. FV-UsIIUsIUR5-SMPGW. FV-HsIIHsIHR5-SMPGW.

73 views • 1 slides

Zang, et al. Supplemental Figure 2

Zang, et al. Supplemental Figure 2. Non-diabetic Diabetic Diabetic+S17834.

97 views • 1 slides

Yoon et al. Supplemental Figure S1

Yoon et al. Supplemental Figure S1. A. B. AGS. MKN-45. N87. CFPAC-1. PANC-1. AGS. MKN-45. N87. CFPAC-1. PANC-1. Monolayer. Monolayer. Monolayer. Monolayer. Monolayer. Monolayer. Monolayer. Monolayer. Monolayer. Monolayer. Spheroid. Spheroid. Spheroid. Spheroid.

112 views • 1 slides

Supplemental Figure Fung et al.

Supplemental Figure Fung et al. A. B. Fluorescence and phase-contrast microscopic images showing ( A ) co-culture of MS5-GFP cells with human primary macrophages (including those encircled red). Note stellate network of MS5 cells (white arrows) spanning across an

138 views • 1 slides

Lim et al, Supplemental Figure S1.

Lim et al, Supplemental Figure S1. OsRING-H2 type : 4 OsRING-HC type : 6 OsRING-v type : 2. OsRING-H2 type : 5 OsRING-HC type : 1 OsRING-v type : 1. OsRING-H2 type : 9 OsRING-HC type : 8 OsRING-v type : 2. OsRING-H2 type : 9 OsRING-HC type : 8 OsRING-v type : 2.

206 views • 14 slides

Yoon et al. Supplemental Figure S3

Yoon et al. Supplemental Figure S3. A. AGS MKN-45 N87. Vismodegib. B. 5-fluoruracil. DMSO. Vismodegib. 5-fluoruracil. Cisplatin. Cisplatin. AGS Spheroid. MKN-45 Spheroid. N87 Spheroid.

124 views • 1 slides

Weaver et al. supplemental Figure 1

Weaver et al. supplemental Figure 1. A BALB/c. Epitope. Immunogen. Peptide. B1. B2. B3. B4. B5. B6. B7. B8. B9. B10. B11. B12. UG37(A). KVTFEPIPIHYCAPA (53). STVQCTHGIRPVVST (62). RIKQIINMWQRVGQA (104). GIVQQQSNLLRAIEAQQHLLKLTVWGIKQLQ (136,137,138,140).

104 views • 3 slides

Geng et al. Supplemental Figure 1

Geng et al. Supplemental Figure 1. murine 3B11 tumor vascular endothelial cells. Human micro-vascular endothelial cells. Analog II. DMSO. Geng et al Supplemental Figure 2. Geng et al Supplemental Figure 3. Geng et al Supplemental Figure 4. Geng et al Supplemental Figure 5.

201 views • 6 slides

Tsutsumi et al., Supplemental Figure 1

80. 40. 80. 60. 0. 40. 10 0. 10 1. 10 2. 10 3. 20. Negative control. GA-FITC. GA-FITC + DMAG-N-oxide. 0. 10 0. 10 1. 10 2. 10 3. Negative control. mock. DMAG-N-oxide. Tsutsumi et al., Supplemental Figure 1. a. Cell Number (%). Fluorescence Intensity (log). b.

69 views • 1 slides

Bush, et al., Supplemental Figure S3.

Bush, et al., Supplemental Figure S3. B. A. C. WT 1. WT1 -- Normal Karyotype. DAPI. KO2 Endoreduplication. Mean = 1.4%. p value = 0.001. KO1 -- 39, XX, -4, chtb(1), chtb(11), chtb(12). KO 2. DAPI. Mean = 4.4%. E. D.

91 views • 1 slides

Supplemental Figure 1 Narainsamy et al.

Supplemental Figure 1 Narainsamy et al. A. B. Supplemental Figure 2 Narainsamy et al. A. B. 3276. 1375. 757. 1438. Supplemental Figure 3 Narainsamy et al. B. Positive ion mode. Negative ion mode. <10. 10-25. 25-35. 35-50. >50. <10. 10-25. 25-35. 35-50. >50. CV (%).

148 views • 7 slides

Supplemental Figure 1 Purandare et al.

Supplemental Figure 1 Purandare et al. A. B. JAK2. 0 Percent Control Cut-Off. 33 Percent Control Cut-Off.

69 views • 1 slides

JH Neltner et al, Supplemental Figure 1

JH Neltner et al, Supplemental Figure 1. Gray matter (green boxes). White matter (yellow boxes). JH Neltner et al, Supplemental Figure 2. A. B. CD 31 CD 34 Collagen IV SMA Factor VIII. C. D. E. F. G. H. I. J.

128 views • 2 slides

Vernin et al., supplemental Figure 5

PI positive cells (%). Vernin et al., supplemental Figure 5.

97 views • 1 slides

Supplemental Figure 1, Ghielmetti et al

Supplemental Figure 1, Ghielmetti et al.

89 views • 1 slides

Supplemental Figure 3, Ghielmetti et al

medium. TB40/E. TB40/E-UV. Supplemental Figure 3, Ghielmetti et al.

98 views • 1 slides

Supplemental Figure 1 Geffroy et al.

CNL-B19. CNL-BA8. l B35. CNL-BA11. l B29. CNL-J11. l J9. Supplemental Figure 1 Geffroy et al. BAT93. JaloEEP558. Genetic position 1. Genetic position 1. 10Kb. CNL-J8. l J39. CNL-JA78. l J107. CNL-J9. l J15. Genetic position 2. CNL-B16. CNL-B17. l B10. Genetic position 3.

103 views • 1 slides

Kiem et al., Supplemental Figure 1

Kiem et al., Supplemental Figure 1. Relative luciferase expression. control. human CCR5-741. human CCR5-1024. macaque CCR5-741. macaque CCR5-1024.

89 views • 1 slides

Glazov et al., Supplemental Figure 6

Glazov et al., Supplemental Figure 6.

119 views • 1 slides

Frietze et al. Supplemental Figure 1

Frietze et al. Supplemental Figure 1.

62 views • 1 slides

More Related